Defence Therapeutics IncGrey Market:DTCFFView on Canadian Exchange
- LAST PRICE0.4093
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.2000/ 25
- Ask / Lots0.7468/ 10
- Open / Previous Close0.4093 / 0.4093
- Day Range
- 52 Week Range
- Volume2
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Yesterday
Nov 22, 2024
Defence Announces Closing of Securities for Debenture Financing, from 7:00PM ET on Friday Nov 22, 2024 by Dow Jones
7:00PM ET on Friday Nov 22, 2024 by Dow Jones
Nov 14, 2024
Defence Therapeutics Announces Securities for Debenture Financing, from 7:31PM ET on Thursday Nov 14, 2024 by Dow Jones
7:31PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors, from 3:16AM ET on Wednesday Nov 13, 2024 by Dow Jones
3:16AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 4, 2024
Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs, from 6:17PM ET on Monday Nov 04, 2024 by Dow Jones
6:17PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Defence Therapeutics Inc | 24.5M | --- | --- |
Company Information
Defence Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and engineering the radio-immuno-conjugate and antibody drug conjugates (ADC) products using its proprietary platform in addition to immune-oncology vaccines. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer and mRNA vaccination.
Contact Information
- Headquarters
- 1680- 200 Burrard StreetVANCOUVER, BC, Canada V6C 3L6
- Phone
- 514-947-2272
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 47.1M |
Defence Therapeutics Inc does not pay a dividend. | |
Beta | 1.37 |
EPS | $-0.26 |
Book Value | $-0.08 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
